Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study
Little is known about the comparison of multiple-gated acquisition (MUGA) scanning with cardiovascular magnetic resonance (CMR) for serial monitoring of HER2+ breast cancer patients receiving trastuzumab. The association of cardiac biomarkers with CMR left ventricular (LV) function and volume is also not well studied. Our objectives were to compare CMR and MUGA for left ventricular ejection fraction (LVEF) assessment, and to examine the association between changes in brain natriuretic peptide (NT-BNP) and troponin-I and changes in CMR LV function and volume. This prospective longitudinal two-centre cohort study recruited HER2+ breast cancer patients between January 2010 and December 2013. MUGA, CMR, NT-BNP and troponin-I were performed at baseline, 6, 12, and 18 months after trastuzumab initiation. In total, 41 patients (age 51.7 ± 10.8 years) were enrolled. LVEF comparison between MUGA and CMR demonstrated weak agreement (Lin’s correlation coefficient r = 0.46, baseline; r = 0.29, 6 months; r = 0.42, 12 months; r = 0.39, 18 months; all p < 0.05). Bland–Altman plots demonstrated wide LVEF agreement limits (pooled agreement limits 3.0 ± 6.2). Both modalities demonstrated significant LVEF decline at 6 and 12 months from baseline, concomitant with increased LV volumes on CMR. Changes in NT-BNP correlated with changes in LV diastolic volume at 12 and 18 months (p < 0.05), and LV systolic volume at 18 months (p < 0.05). Changes in troponin-I did not correlate with changes in LV function or volume at any timepoint. In conclusion, CMR and MUGA LVEF are not interchangeable, warranting selection and utility of one modality for serial monitoring. CMR is useful due to less radiation exposure and accuracy of LV volume measurements. Changes in NT-BNP correlated with changes in LV volumes.
KeywordsBreast cancer Trastuzumab Cardiotoxicity Cardiovascular magnetic resonance MUGA LVEF
We would like to thank all the study participants who contributed their time to this research study. We also acknowledge the study coordinators for their efforts in data collection. This work was supported by a Canadian Institute of Health Research Industry partnered grant with Hoffman-La Roche Canada Inc.
This work was supported by a Canadian Institute of Health Research Industry partnered grant with Hoffman-La Roche Canada Inc.
Compliance with ethical standards
Conflict of Interest
C. Brezden-Masley has received research grant support and/or honoraria for educational activities and/or served as consultant to Roche.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committees (St. Michael’s Hospital and Sunnybrook Odette Cancer Centre) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 11.Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274. https://doi.org/10.1200/JCO.2005.04.173 CrossRefGoogle Scholar
- 16.Bellenger NG, Burgess MI, Ray SG et al (2000) Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable? Eur Heart J 21:1387–1396. https://doi.org/10.1053/euhj.2000.2011 CrossRefGoogle Scholar
- 22.Redfield MM, Rodeheffer RJ, Jacobsen SJ et al (2004) Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction. Circulation 109:3176–3181. https://doi.org/10.1161/01.CIR.0000130845.38133.8F CrossRefGoogle Scholar
- 26.Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749–2755. https://doi.org/10.1161/01.CIR.0000130926.51766.CC CrossRefGoogle Scholar
- 27.Barthur A, Brezden-Masley C, Connelly KA et al (2017) Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson 19:44. https://doi.org/10.1186/s12968-017-0356-4 CrossRefGoogle Scholar
- 31.Walker J, Bhullar N, Fallah-rad N et al (2010) Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 28:3429–3436. https://doi.org/10.1200/JCO.2009.26.7294 CrossRefGoogle Scholar
- 33.Grover S, DePasquale C, Leong DP et al (2012) Early cardiac changes following anthracycline chemotherapy in breast cancer: a prospective multi-centre study using advanced cardiac imaging and biochemical markers. J Cardiovasc Magn Reson 14(Suppl 1):181. https://doi.org/10.1186/1532-429X-14-S1-P181 CrossRefGoogle Scholar
- 34.Fallah-Rad N, Walker JR, Wassef A et al (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with a. J Am Coll Cardiol 57:2263–2270. https://doi.org/10.1016/j.jacc.2010.11.063 CrossRefGoogle Scholar
- 36.Drafts BC, Twomley KM, D'Agostino R et al (2014) Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 6(8):877–885. https://doi.org/10.1016/j.jcmg.2012.11.017.Low CrossRefGoogle Scholar